Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Development and Registration is Scopus-indexed (Q3, CiteScore 1.1), DOAJ. Published by Center of Pharmaceutical Analytics.
Checked against the index lists dated .
ISSN 2305-2066Verify ISSN ↗2658-5049Verify ISSN ↗
Publisher: Center of Pharmaceutical Analytics
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacy | 30 / 52 | 43rd | Q3 |
| Pharmaceutical Science | 135 / 191 | 29th | Q3 |
| Drug Discovery | 141 / 161 | 12th | Q4 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q3, CiteScore 1.1.
Drug Development and Registration is Q3 in Pharmacy (rank 30 of 52), Q3 in Pharmaceutical Science (rank 135 of 191) and Q4 in Drug Discovery (rank 141 of 161), by CiteScore 2025.
Drug Development and Registration is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 1.1, quartile Q3, 43rd percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.189, quartile Q3, with an H-index of 10.
Drug Development and Registration is published by Center of Pharmaceutical Analytics. Its print ISSN is 2305-2066 and its online ISSN is 2658-5049.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Drug Development and Registration has an h-index of 11 and a 2-year mean of 0.69 citations per paper (OpenAlex). Its Scopus CiteScore is 1.1, quartile Q3. On 2-year citations it ranks #28 of 50 Scopus journals in Pharmacy.
Drug Development and Registration published 81 papers in 2025; its busiest recent year was 2023 with 119. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 94 research articles (2025–2026), authors are most often from Russia (90.8%), Iraq (2.7%) and Kazakhstan (2.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.